Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy

Updates of mTOR Inhibitors

(2012) Hongyu Zhou et al.   Anti-Cancer Agents in Medicinal Chemistry

ATP-Competitive Inhibitors of mTOR: An Update

(2011) S. Schenone et al.   CURRENT MEDICINAL CHEMISTRY

Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas

(2011) Sant P. Chawla et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumor Activity of Ridaforolimus and Potential Cell-Cycle Determinants of Sensitivity in Sarcoma and Endometrial Cancer Models

(2011) R. M. Squillace et al.   MOLECULAR CANCER THERAPEUTICS

Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens

(2011) V. M. Rivera et al.   MOLECULAR CANCER THERAPEUTICS

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2010) P. C. W. Hogendoorn et al.   ANNALS OF ONCOLOGY

Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2010) P. G. Casali et al.   ANNALS OF ONCOLOGY

Osteosarcoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

(2009) S. Bielack et al.   ANNALS OF ONCOLOGY

A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies

(2009) C. M. Hartford et al.   CLINICAL CANCER RESEARCH

Enhancing mTOR-targeted cancer therapy

(2009) Xuerong Wang et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors

(2009) Yoh Dobashi et al.   MODERN PATHOLOGY

Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies

(2008) Monica M. Mita et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET

Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis

(2008) John J. Bissler et al.   NEW ENGLAND JOURNAL OF MEDICINE